In the media

Admedus 2017 Annual General Meeting webinar

17, November, 2017

Posted In: Featured, In the media

The investor webinar from our AGM on 16 November 2017 is now available to view via this link – AHZ – AGM 16 November 2017

> Read more

Admedus announces facility agreement with Partners for Growth

26, October, 2017

Posted In: Featured, In the media

Admedus Ltd today announced that it has entered into an agreement with Partners for Growth (PFG) for a secured debt facility of up to AUD $10 million. Based in the San Francisco Bay area, PFG is a partnership that provides capital funding debt solutions to private and public technology and life science companies. Read full […]

> Read more

Admedus TAVR project on track with new IP applications

24, October, 2017

Posted In: Featured, In the media, Blog

Admedus Ltd today announced that it has submitted IP applications relating to the development of a new Transcatheter Aortic Valve Replacement (TAVR) device. Read the full ASX statement here.

> Read more

New neck and head cancer treatment a step closer to trials

23, October, 2017

Posted In: Featured, In the media

As reported widely across Australian media outlets, Admedus Immunotherapies recently received a $250,000 Government grant from the Advance Queensland Ignite Ideas Fund to support human clinical trials, led by Professor Ian Frazer, of a new vaccine that could be used to treat head and neck cancer. Find a copy of the story on News.com,  7 News  or Brisbane Times. Read the full […]

> Read more

Investor webinar 5 September 2017

1, September, 2017

Posted In: Featured, In the media, Videos, Blog

Admedus Limited (ASX: AHZ) held an investor webinar on 5 September, 2017 to discuss the results of the Company’s Preliminary Final Report (Appendix 4E) for the year ended 30 June 2017.  Admedus CEO Wayne Paterson will provide a review of the Company’s year-end performance as well as operational and business highlights.

> Read more

Admedus announces exclusive supply agreement with 4C Medical

Admedus announces exclusive supply agreement with 4C Medical

31, August, 2017

Posted In: In the media, Blog

Admedus Limited is pleased to announce that it has entered an exclusive supply agreement with 4C Medical Technologies, Inc. (4C Medical), a Minnesota-based developer of minimally invasive therapies for structural heart disease. Read more here.

> Read more

Admedus beats revenue forecasts for financial year 2017

31, August, 2017

Posted In: Featured, In the media

Admedus has delivered a full year sales increase of 58% to $22.3 million for financial year 2017, compared to the previous financial year. Read more here.

> Read more

Sponsorship supports kids with heart disease

15, August, 2017

Posted In: Featured, In the media

Admedus Ltd is proud to announce a six-month $20k sponsorship of the HeartKids Education Program which provides vital resources for families of children living with congenital/childhood heart disease. In Australia, congenital/childhood heart disease is the leading cause of death for children under a year old and nearly three thousand babies are born with a heart […]

> Read more

Admedus Ltd readies commercial CardioCel® 3D launch

11, July, 2017

Posted In: Featured, In the media

Proactive Investors takes a look at our plans for CardioCel 3D. Read their latest article here.

> Read more

Admedus CEO Wayne Paterson interview with Proactive Investors

4, July, 2017

Posted In: In the media, Videos

Our CEO Wayne Paterson recently shared his thoughts and vision for Admedus in this interview with Proactive Investors. Watch it now.

> Read more